Research programme: protease inhibitors - Consensus/Vertex
Latest Information Update: 01 May 2007
At a glance
- Originator Consensus Pharmaceuticals; Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 01 May 2007 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 13 Jul 2001 Preclinical development for Undefined in USA (unspecified route)